Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy.
UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Cellectis is implementing good security practices.
Read more about the latest issues in cybersecurity
WannaCry is a ransomware cryptoworm cyber attack that targets computers running the Microsoft ...
Data is rapidly becoming one of the most valuable assets in the modern world. The digital giants ...
Compare Cellectis's security performance with other companies